

Tetrahedron Letters

Tetrahedron Letters 46 (2005) 419-422

2-Acylimino-3-alkyl-3H-thiazoline derivatives: one-pot, three-component condensation synthesis of novel β -turn mimics

Akira Manaka,* Takaaki Ishii, Keiko Takahashi and Masakazu Sato

Medicinal Chemistry Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd, 403, 1-chome, Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan

Received 20 August 2004; revised 17 November 2004; accepted 19 November 2004

Abstract—One-pot, three-component condensation of aroylthiourea, primary amine and α -halocarbonyl derivatives for the synthesis of 2-acylimino-3-alkyl-3*H*-thiazoline derivatives is described. This method is useful for simultaneously incorporating diverse functional groups at four positions in the 3*H*-thiazoline skeleton to obtain β -turn tripeptide mimics. © 2004 Elsevier Ltd. All rights reserved.

The β-turn structure is formed by intramolecular hydrogen bonding in a tripeptide substructure at the protein surface, and is well known to be recognized as a ligand by various receptors.¹ Numerous studies have been conducted on low-molecular-weight compounds, which mimic the β-turn substructure of natural polypeptide ligands to overcome the pharmacokinetic disadvantages of peptide ligands. Several low-molecular-weight mimics of the RGD sequence on fibringen have been reported, and these exhibit strong inhibitory activities against the binding of fibrinogen to its receptor GPIIb/IIIa.2 We have also reported a unique 3-alkyl-3H-thiazoline derivative PS-028 (1) as a potent and selective GPIIb/IIIa antagonist (Fig. 1, $K_1 = 46.5 \pm 5.8 \text{ pM}$).³ The 3-alkyl-3H-thiazoline skeleton of PS-028 can be functionalized at four positions, and therefore has potential as a versatile template for other β-turn mimics. In course of an investigation of functionalization on 3-alkyl-3H-thiazoline skeleton, we have found that the introduction of a substituent other than a small alkyl group at the 3-posi-

Figure 1.

tion of the skeleton is limited by the low reactivity toward alkyl halides (Scheme 1). As an alternative method to prepare 3-alkyl-3H-thiazoline skeleton, condensation reaction of N-acyl-N'-alkylthiourea and α -halocarbonyl derivative is reported. However, there are few examples to apply this method for functionalization on the 3H-thiazoline ring system (Scheme 2). Therefore, we explored a versatile method for the introduction of functional groups on the 3-alkyl-3H-thiazoline skeleton using various acyl thioureas and α -halocarbonyl reagents by a one-pot, three-component condensation.

Scheme 1.

Keywords: Thiazoline; One-pot procedure; β-Turn mimic.

^{*} Corresponding author. Tel.: +81 48 669 3072; fax: +81 48 652 7254; e-mail: akira.manaka@po.rd.taisho.co.jp

$$Bz-N \stackrel{S}{\underset{H}{\bigvee}} R \stackrel{O}{\underset{alcohol reflux}{\bigvee}} X \\ BzN \stackrel{S}{\underset{R}{\bigvee}} R$$

Scheme 2.

The efficient synthetic method for 3-alkyl-3*H*-thiazoline is shown in Scheme 3. Thus, aroylisothiocyanates 5 prepared from the corresponding acyl chlorides 4 and ammonium thiocyanate⁵ reacted smoothly with various amines to afford acylthioureas 6. Without isolation, these intermediates were condensed with α-halocarbonyl derivatives to construct a 3-alkyl-3H-thiazoline template. The configuration of the acylimino moiety was confirmed to be syn by direct comparison of its melting point and spectral data with those of the authentic 3-nbutyl derivative synthesized by the previous method.³ The *syn* selectivity in this reaction is likely due to the steric hindrance of the acyl group and the R² group in the isothiourea intermediates. As shown in Scheme 3, elimination of hydrogen halide from sulfonium intermediates 7 proceed via route A so as to avoid intermolecular steric hindrance (route B).

The reaction was performed in a non-polar solvent such as benzene, toluene or xylene at reflux temperature with water separator for the efficient removal of water and hydrogen chloride generated by the reaction. For the less soluble acylthiourea derivatives (e.g., R = Ph), acetic acid was preferable for the solvent to accelerate the reaction. In that case, the yield and purity of the product were slightly decreased (entries 3 and 10). Contrary to the description in the previous paper,⁴ reactions in ethanol or with a base such as potassium carbonate or trieth-

ylamine did not proceed and gave unidentified yellow precipitates. At least 2 equiv of α -halocarbonyl reagent were necessary for the reaction to proceed to completion. When the reaction was performed with 1 equiv of α -halocarbonyl reagent, the reaction stopped when about half of the acylthiourea was consumed.

The variety of the substituents R¹–R⁴ are summarized in Table 1. With regard to R¹, while aromatic derivatives with both electron-withdrawing and -donating groups were suitable for this reaction, alkyl derivatives were not (entries 19 and 20). The reaction of acetyl isothiocyanate or phenylacetyl isothiocyanate with primary amines gave the corresponding amides instead of acylthiourea derivatives.

The introduction of an R² group with primary amines was widely tolerated. For example, 3-isopropyl-3Hthiazoline derivatives, which required several days at room temperature by alkylation of 2 (Scheme 1), were obtained in yields of 77-92% with only a few hours operation (entries 1, 12, 14). This procedure also made it possible to introduce a cycloalkyl group (entries 4-7), a phenyl group (entries 10 and 11) and a functionalized alkyl group (entries 7 and 8) as R². However, introduction of a methyl group failed due to the insolubility of the intermediate thiourea derivative. Condensation of the acylthiourea intermediate with 2-chloroacetylacetone, chloroacetone or diethyl 2-bromomalonate smoothly gave the corresponding products, which possessed an acetyl group, a hydrogen atom and an ethoxycarbonyl group as R³, and methyl, and hydroxyl groups as R⁴ (entries 16–18). In addition, the introduction of amino moieties to the R⁴ methyl group was achieved by bromination with N-bromosuccinimide in the presence of N,N-azobis(isobutyronitrile), followed by treatment with amines.³

$$R^{1} \xrightarrow{\text{O}} \underbrace{\begin{array}{c} \text{NH}_{4}\text{SCN} \\ \text{acetone} \\ \text{reflux, 30 min} \end{array}}_{\text{reflux, 30 min}} R^{1} \xrightarrow{\text{N=C=S}} \underbrace{\begin{array}{c} R^{2}\text{NH}_{2} \\ \text{to} \\ \text{to} \\ \text{reflux} \end{array}}_{\text{formula}} R^{1} \xrightarrow{\text{N=C=S}} \underbrace{\begin{array}{c} R^{2}\text{NH}_{2} \\ \text{to} \\ \text{reflux} \end{array}}_{\text{formula}} R^{1} \xrightarrow{\text{N=C=S}} \underbrace{\begin{array}{c} R^{2}\text{NH}_{2} \\ \text{N=C=S} \\ \text{N=M} \\ \text{N=M} \\ \text{N=C=S} \\ \text{N=M} \\$$

Table 1. The yields of 3*H*-thiazoline derivatives

$$R^{1} \bigvee_{N=1}^{O} S \bigvee_{R^{4}}^{R^{3}} R^{4}$$

Entry ^a	R^1	R^2	R^3	R^4	Solvent	Compound no.	Yield (%) ^b
1	4-CN-C ₆ H ₄ -	Isopropyl	CO ₂ Et	Me	Toluene	8	77
2	$4-CN-C_6H_4-$	n-Butyl	CO ₂ Et	Me	Toluene	9	55
3	$4-CN-C_6H_4-$	Isopentyl	CO ₂ Et	Me	AcOH	10	77
4	$4-CN-C_6H_4-$	Cyclopropyl	CO_2Et	Me	Toluene	11	64
5	$4-CN-C_6H_4-$	Cyclobutyl	CO_2Et	Me	Toluene	12	66
6	4 -CN $-$ C $_6$ H $_4$ $-$	Cyclopentyl3	CO_2Et	Me	Toluene	13	62
7	4-CN-C ₆ H ₄ -	ОН	CO ₂ Et	Me	Toluene	14	63
8	$4-CN-C_6H_4-$	(CH ₂) ₅ CO ₂ -t-butyl	CO_2Et	Me	Toluene	15	46
9	$4-CN-C_6H_4-$	CH ₂ Ph	CO ₂ Et	Me	Toluene	16	66
10	4-CN-C ₆ H ₄ -	Ph	CO ₂ Et	Me	AcOH	17	40
11	$4-CN-C_6H_4-$	$3-(OH)C_6H_4$	CO ₂ Et	Me	Toluene	18	79
12	$4-NO_2-C_6H_4-$	Isopropyl	CO_2Et	Me	Toluene	19	86
13	$4-NO_2-C_6H_4-$	Isopentyl	CO_2Et	Me	Toluene	20	79
14	$4\text{-OMe-}C_6H_4-$	Isopropyl	CO_2Et	Me	Toluene	21	92
15	$2,5-(OMe)_2-C_6H_3-$	Isobutyl	CO_2Et	Me	Mesitylene	22	35
16	$4\text{-CO}_2\text{Me-C}_6\text{H}_4$	n-Hexyl	COMe	Me	Toluene	23	95
17	$4-NO_2-C_6H_4-$	Isopentyl	H	Me	Toluene	24	81
18	$4-NO_2-C_6H_4-$	Isopentyl	CO ₂ Et	OH	Neat	25	36
19	Me	n-Butyl	_	_	Toluene		c
20	$4-NO_2-C_6H_4CH_2-$	n-Butyl	_	_	Toluene		c

^a Entries 1–15: ethyl 2-chloroacetoacetate, entry 16: 3-chloroacetylacetone, entry 17: chloroacetone, entry 18: ethyl 2-bromomalonate was used as a α-halocarbonyl reagent.

To confirm the versatility of the one-pot, three-component synthesis of 3H-thiazoline template, we have applied for construction of a low-molecular-weight VLA-4 (very late antigen-4) antagonist library. A variety of substituents, which could correspond to amino acid side chain moieties of the Ile-Asp-Ser β -turn sequence on VCAM-1 (vascular cell adhesion molecule-1, which are recognized by VLA- 4^7 was introduced to the R^1 - R^4 to give compound 27 as a specific inhibitor with moderate potency (IC50, 5.6 μ M) (Scheme 4).

In summary, we have developed a one-pot, three-component condensation procedure for the synthesis of a 3*H*-thiazoline template, which enables introduction of diverse functional groups at four positions simulta-

neously. We also exemplified that the method is widely applicable as a low-molecular-weight β -turn mimic.

Typical procedure for the synthesis of substituted 3*H*-thiazoline derivatives: to a mixture of arylisothiocyanate 5 in toluene was added an appropriate amine (1.0 equiv) and the mixture was stirred under reflux for 5 min. After the addition of α -halocarbonyl reagent (2.0 equiv), the reaction mixture was stirred under reflux with removal of the generated water by a Dean–Stark apparatus for 2–4 h. The reaction mixture was cooled to ambient temperature with stirring and the resulting precipitates were collected by filtration to give 3-alkyl-3*H*-thiazoline derivatives 8–25 in yields of 35–95%.

Scheme 4. Reagents and conditions: (a) 10% aq NaOH/MeOH–CH₂Cl₂; (b) D-Ala-OH·HCl, WSC·HCl, HOBt·H₂O/DMF; (c) 10% Pd/c, HCO₂NH₄/MeOH; (d) 3-CF₃-C₆H₄COCl, Et₃N/CH₂Cl₂; (e) TFA.

^b Yield based on acylisothiocyanate.

^c n-Butylamide was obtained instead of acylisothiocyanate.

Acknowledgements

The authors acknowledge Mr. Yoshihisa Toda for evaluating the VLA-4-inhibitory activity of 27.

References and notes

- McDowell, R. S.; Gadek, T. R. J. Am. Chem. Soc. 1992, 114, 9245–9253.
- For review, see: Salam, A. M.; Suwaidi, J. A. Exp. Opin. Invest. Drugs 2002, 11, 1645–1658.
- Manaka, A.; Sato, M.; Aoki, M.; Tanaka, M.; Ikeda, T.; Toda, Y.; Yamane, Y.; Nakaike, S. *Bioorg. Med. Chem. Lett.* 2001, 11, 1031–1035.

- (a) Murav'eva, K. M.; Shchukina, M. N. Zh. Obshch. Khim. 1960, 30, 2327–2334; (b) Murav'eva, K. M.; Shchukina, M. N. Zh. Obshch. Khim. 1960, 30, 2334–2340.
- Frank, R. L.; Smith, P. V. Org. Synth. Coll. 1955, 3, 735.
- (a) Osborn, L.; Vassallo, C.; Browning, B. G.; Tizard, R.; Haskard, D. O.; Benjamin, C. D.; (b) Renz, M. E.; Chiu, H. H.; Jones, S.; Fox, J.; Kim, K. J.; Presta, L. G.; Fong, S. J. Cell Biol. 1994, 125, 1395–1406
- For review, see: Jackson, D. Y. Curr. Pharm. Design 2002, 8, 1229–1253.
- Sato, M.; Ishii, T. JP Patent 2001002664, 2001; Chem. Abstr. 2001, 134, 86542.